ASMANEX HFA Rx
Generic Name and Formulations:
Mometasone furoate 100mcg, 200mcg; per actuation; metered-dose inhaler with dose counter.
Merck & Co., Inc.
Indications for ASMANEX HFA:
Maintenance treatment of asthma as prophylactic therapy.
Limitations Of use:
Not for relief of acute bronchospasm.
Previously on inhaled medium-dose corticosteroids: use 100mcg strength. Previously on inhaled high-dose or oral corticosteroids (wean gradually): use 200mcg strength. For both: Two inhalations twice daily (AM & PM). Rinse mouth after use.
Primary treatment of status asthmaticus or acute asthma attacks.
Maintain regular regimen. Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Re-evaluate immediately during rapidly deteriorating asthma; may need oral corticosteroid therapy. Immunosuppressed. Untreated infections (eg, fungal, bacterial, viral, parasitic), TB, ocular herpes simplex. If exposed to chickenpox or measles, consider anti-infective prophylactic therapy. Transferring from systemic steroids: taper gradually. If adrenal insufficiency exists following systemic corticosteroids, replacement with inhaled steroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude). Monitor for increased intraocular pressure, glaucoma, and/or cataracts; bone mineral density if other osteoporosis risk factors exist; and for growth suppression in children; hypercorticism and HPA axis suppression (if occurs, discontinue gradually). Severe hepatic impairment. Labor & delivery. Pregnancy. Nursing mothers: not recommended.
Potentiated by ketoconazole or other strong CYP3A4 inhibitors (eg, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin); use caution.
Nasopharyngitis, headache, sinusitis, bronchitis, influenza; hypersensitivity reactions, paradoxical bronchospasm; discontinue if occurs.
Inhaler—13g (120 inh)
Endocrinology Advisor Articles
- Higher BUN May Increase Risk for Incident Diabetes
- Efficacy of Novel GLP-1 Receptor Agonist Drug Device Examined
- Takeout Food May Increase Adverse Health Consequences in Children
- Nonhormonal Options Available for Menopause Symptom Relief
- Plasma Volume Changes Mediate Risk of CV Mortality With Empagliflozin
- New Consensus Recommendations on Use of Continuous Glucose Monitoring
- Does Genetic Susceptibility Lead to Late-Onset Type 1 Diabetes?
- Clinical Outcomes in T2D: Low-Carbohydrate vs Calorie-Restricted Diet
- New Continuous Glucose Monitoring System Now Available for Medicare Patients
- Text Message-Delivered Interventions Effective for Weight Management
- Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D
- Gastric Bypass vs Sleeve Gastrectomy Outcomes in Morbid Obesity
- Acute Kidney Injury Increases Risk for Postdischarge Hypoglycemia in Diabetes
- Novel Deep Learning System May Help Identify Diabetic Retinopathy
- Trends in CVD, Risk Factors, and Medications in Children With T1D